PDGF-BB exhibited therapeutic effects on rat model of bisphosphonate-related osteonecrosis of the jaw by enhancing angiogenesis and osteogenesis.

[1]  O. Ferreira Júnior,et al.  Treatment of bisphosphonate-related osteonecrosis using platelet-rich plasma: microtomographic, microscopic, and immunohistochemical analyses. , 2019, Brazilian oral research.

[2]  C. Pautke,et al.  Is the conservative non-surgical management of medication-related osteonecrosis of the jaw an appropriate treatment option for early stages? A long-term single-center cohort study. , 2019, Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery.

[3]  Xiao-mei Lao,et al.  Interaction of cancer cell‐derived Foxp3 and tumor microenvironment in human tongue squamous cell carcinoma , 2018, Experimental cell research.

[4]  M. Elsalanty,et al.  Removal of matrix-bound zoledronate prevents post-extraction osteonecrosis of the jaw by rescuing osteoclast function. , 2018, Bone.

[5]  N. Ishkitiev,et al.  Role of PDGF-BB in proliferation, differentiation and maintaining stem cell properties of PDL cells in vitro. , 2018, Archives of oral biology.

[6]  S. Kuroshima,et al.  Effect of anti-angiogenesis induced by chemotherapeutic monotherapy, chemotherapeutic/bisphosphonate combination therapy and anti-VEGFA mAb therapy on tooth extraction socket healing in mice , 2018, Journal of Bone and Mineral Metabolism.

[7]  Xiao-mei Lao,et al.  Zoledronate suppressed angiogenesis and osteogenesis by inhibiting osteoclasts formation and secretion of PDGF-BB , 2017, PloS one.

[8]  Junqing Ma,et al.  GATA4 regulates osteoblastic differentiation and bone remodeling via p38-mediated signaling , 2017, Journal of Molecular Histology.

[9]  T. Okano,et al.  Multipotent mesenchymal stromal cell sheet therapy for bisphosphonate-related osteonecrosis of the jaw in a rat model. , 2016, Acta biomaterialia.

[10]  M. Ehrenfeld,et al.  Fluorescence-guided surgery for the treatment of medication-related osteonecrosis of the jaw: A prospective cohort study. , 2016, Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery.

[11]  Jiamin Zhang,et al.  Tissue-Specific Progenitor and Stem Cells Platelet-Derived Growth Factor-BB Protects Mesenchymal Stem Cells ( MSCs ) Derived From Immune Thrombocytopenia Patients Against Apoptosis and Senescence and Maintains MSC-Mediated Immunosuppression , 2016 .

[12]  Gong Yang,et al.  Rap1A Regulates Osteoblastic Differentiation via the ERK and p38 Mediated Signaling , 2015, PloS one.

[13]  A. Abarrategi,et al.  Adipose-derived stem cells and platelet-rich plasma for preventive treatment of bisphosphonate-related osteonecrosis of the jaw in a murine model. , 2015, Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery.

[14]  M. Elsalanty,et al.  A Model for Osteonecrosis of the Jaw with Zoledronate Treatment following Repeated Major Trauma , 2015, PloS one.

[15]  Seiji Nakamura,et al.  Evaluation of the therapeutic effects of conditioned media from mesenchymal stem cells in a rat bisphosphonate-related osteonecrosis of the jaw-like model. , 2015, Bone.

[16]  H. Schwartz.  American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update and CTX. , 2015, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[17]  B. Olsen,et al.  Bone development. , 2015, Bone.

[18]  L. Duong,et al.  PDGF-BB secreted by preosteoclasts induces CD31hiEmcnhi vessel subtype in coupling osteogenesis , 2014, Nature Medicine.

[19]  R. Adams,et al.  Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone , 2014, Nature.

[20]  A. Pabst,et al.  Bisphosphonates’ antiangiogenic potency in the development of bisphosphonate-associated osteonecrosis of the jaws: influence on microvessel sprouting in an in vivo 3D Matrigel assay , 2014, Clinical Oral Investigations.

[21]  G. Dorado,et al.  Risedronate positively affects osteogenic differentiation of human mesenchymal stromal cells. , 2013, Archives of medical research.

[22]  S. Shi,et al.  Allogeneic mesenchymal stem cell therapy for bisphosphonate-related jaw osteonecrosis in Swine. , 2013, Stem cells and development.

[23]  R. Civitelli,et al.  Risedronate increases osteoblastic differentiation and function through connexin43. , 2013, Biochemical and biophysical research communications.

[24]  Jie Han,et al.  Zoledronate Attenuates Angiogenic Effects of Angiotensin II-Stimulated Endothelial Progenitor Cells via RhoA and MAPK Signaling , 2012, PloS one.

[25]  S. Patntirapong,et al.  Zoledronic acid suppresses mineralization through direct cytotoxicity and osteoblast differentiation inhibition. , 2012, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[26]  M. Imano,et al.  Bisphosphonate- and statin-induced enhancement of OPG expression and inhibition of CD9, M-CSF, and RANKL expressions via inhibition of the Ras/MEK/ERK pathway and activation of p38MAPK in mouse bone marrow stromal cell line ST2 , 2012, Molecular and Cellular Endocrinology.

[27]  I. Reid,et al.  Epidemiology and pathogenesis of osteonecrosis of the jaw , 2012, Nature Reviews Rheumatology.

[28]  J. Penninger,et al.  Lineage‐committed osteoclast precursors circulate in blood and settle down into bone , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[29]  I. Reid,et al.  Bone-bound bisphosphonate inhibits growth of adjacent non-bone cells. , 2011, Bone.

[30]  R. Russell,et al.  Bisphosphonates: the first 40 years. , 2011, Bone.

[31]  F. Luyten,et al.  Does tranexamic acid stabilised fibrin support the osteogenic differentiation of human periosteum derived cells? , 2011, European cells & materials.

[32]  V. Castronovo,et al.  Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase. , 2011, Bone.

[33]  A. Mikos,et al.  Fibrin glue as a drug delivery system. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[34]  J. Penninger,et al.  Identification of cell cycle–arrested quiescent osteoclast precursors in vivo , 2009, The Journal of cell biology.

[35]  M. Marra,et al.  Emerging anti-cancer molecular mechanisms of aminobisphosphonates. , 2006, Endocrine-related cancer.

[36]  M. Dimopoulos,et al.  Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  I. Martin,et al.  Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells. , 2005, Biomaterials.

[38]  Johnny Huard,et al.  VEGF Improves, Whereas sFlt1 Inhibits, BMP2‐Induced Bone Formation and Bone Healing Through Modulation of Angiogenesis , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[39]  H. Schwartz.  Bisphosphonate-associated osteonecrosis of the jaws. , 2005, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[40]  R. Marx.  Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. , 2003, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[41]  Xiaodong Feng,et al.  Angiogenesis in wound healing. , 2000, The journal of investigative dermatology. Symposium proceedings.